179 related articles for article (PubMed ID: 24793026)
1. Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus.
Khalaf N; Nguyen T; Ramsey D; El-Serag HB
Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1832-9.e6. PubMed ID: 24793026
[TBL] [Abstract][Full Text] [Related]
2. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
Thrift AP; Anderson LA; Murray LJ; Cook MB; Shaheen NJ; Rubenstein JH; El-Serag HB; Vaughan TL; Schneider JL; Whiteman DC; Corley DA
Am J Gastroenterol; 2016 Nov; 111(11):1528-1535. PubMed ID: 27575711
[TBL] [Abstract][Full Text] [Related]
3. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus.
Schneider JL; Zhao WK; Corley DA
Dig Dis Sci; 2015 Feb; 60(2):436-43. PubMed ID: 25213077
[TBL] [Abstract][Full Text] [Related]
4. The use of nonsteroidal anti-inflammatory drugs and the risk of Barrett's oesophagus.
Thrift AP; Pandeya N; Smith KJ; Green AC; Webb PM; Whiteman DC
Aliment Pharmacol Ther; 2011 Nov; 34(10):1235-44. PubMed ID: 21967506
[TBL] [Abstract][Full Text] [Related]
5. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
Wang F; Lv ZS; Fu YK
Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
[TBL] [Abstract][Full Text] [Related]
6. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence.
Anderson LA; Johnston BT; Watson RG; Murphy SJ; Ferguson HR; Comber H; McGuigan J; Reynolds JV; Murray LJ
Cancer Res; 2006 May; 66(9):4975-82. PubMed ID: 16651456
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis.
Liao LM; Vaughan TL; Corley DA; Cook MB; Casson AG; Kamangar F; Abnet CC; Risch HA; Giffen C; Freedman ND; Chow WH; Sadeghi S; Pandeya N; Whiteman DC; Murray LJ; Bernstein L; Gammon MD; Wu AH
Gastroenterology; 2012 Mar; 142(3):442-452.e5; quiz e22-3. PubMed ID: 22108196
[TBL] [Abstract][Full Text] [Related]
8. Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.
Beales IL; Dearman L; Vardi I; Loke Y
Dig Dis Sci; 2016 Jan; 61(1):238-46. PubMed ID: 26386857
[TBL] [Abstract][Full Text] [Related]
9. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Nguyen DM; Richardson P; El-Serag HB
Gastroenterology; 2010 Jun; 138(7):2260-6. PubMed ID: 20188100
[TBL] [Abstract][Full Text] [Related]
10. Statin use is associated with a decreased risk of Barrett's esophagus.
Nguyen T; Khalaf N; Ramsey D; El-Serag HB
Gastroenterology; 2014 Aug; 147(2):314-23. PubMed ID: 24798416
[TBL] [Abstract][Full Text] [Related]
11. Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.
Loomans-Kropp HA; Chaloux M; Richmond E; Umar A
Cancer Prev Res (Phila); 2021 Feb; 14(2):195-204. PubMed ID: 32998939
[TBL] [Abstract][Full Text] [Related]
12. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
13. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
14. Effect of nonsteroidal anti-inflammatory drugs on Barrett's esophagus risk: a systematic review and meta-analysis.
Zhang J; Wu H; Wang R
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101552. PubMed ID: 33268293
[TBL] [Abstract][Full Text] [Related]
15. Persistence of nondysplastic Barrett's esophagus identifies patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort.
Gaddam S; Singh M; Balasubramanian G; Thota P; Gupta N; Wani S; Higbee AD; Mathur SC; Horwhat JD; Rastogi A; Young PE; Cash BD; Bansal A; Vargo JJ; Falk GW; Lieberman DA; Sampliner RE; Sharma P
Gastroenterology; 2013 Sep; 145(3):548-53.e1. PubMed ID: 23714382
[TBL] [Abstract][Full Text] [Related]
16. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
17. Dietary antioxidants and risk of Barrett's esophagus and adenocarcinoma of the esophagus in an Australian population.
Ibiebele TI; Hughes MC; Nagle CM; Bain CJ; Whiteman DC; Webb PM;
Int J Cancer; 2013 Jul; 133(1):214-24. PubMed ID: 23292980
[TBL] [Abstract][Full Text] [Related]
18. Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use.
Siersema PD; Yu S; Sahbaie P; Steyerberg EW; Simpson PW; Kuipers EJ; Triadafilopoulos G
Gastrointest Endosc; 2006 Apr; 63(4):581-6. PubMed ID: 16564855
[TBL] [Abstract][Full Text] [Related]
19. Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study.
Garcia JM; Splenser AE; Kramer J; Alsarraj A; Fitzgerald S; Ramsey D; El-Serag HB
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):229-238.e3. PubMed ID: 23954649
[TBL] [Abstract][Full Text] [Related]
20. No significant effects of smoking or alcohol consumption on risk of Barrett's esophagus.
Thrift AP; Kramer JR; Richardson PA; El-Serag HB
Dig Dis Sci; 2014 Jan; 59(1):108-16. PubMed ID: 24114046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
